AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34865278 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 75
Study 34865278 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + subcision
Number of subjects: 75
Study 34865278 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + combined peeling (GA 70% + TCA 35%)
Number of subjects: 75
Study 34865278 — intervention group
Group type: COMPARATOR
Intervention: Control group (contralateral side of each patient)
Number of subjects: 75
Study 33804738 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Continuous Exercise (ACE)
Number of subjects: 36
Study 33804738 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 36
Study 33804738 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Exercise (CE)
Number of subjects: 36
Study 32555939 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.5‐mg/kg bolus followed by infusion at 15 µg/kg/min)
Number of subjects: 40
Study 32555939 — intervention group
Group type: COMPARATOR
Intervention: Saline (30 mL bolus and infusion)
Number of subjects: 40
Study 33576244 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent BPD group (aged 15 to 17 years; n = 64)
Number of subjects: 139
Study 33576244 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adult BPD group (aged 18 to 25 years; n = 75)
Number of subjects: 139
Study 33576244 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 139
Study 33576244 — intervention group
Group type: COMPARATOR
Intervention: Comparison of adolescents and young adults
Number of subjects: 139
Study 34321278 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab and lapatinib
Number of subjects: 455
Study 35189830 — intervention group
Group type: EXPERIMENTAL
Intervention: VECTRON™ T500 (broflanilide 50% WP)
Number of subjects: 16
Study 35189830 — intervention group
Group type: COMPARATOR
Intervention: Fludora® Fusion (clothianidin 50% WP + deltamethrin 6.25% WP)
Number of subjects: 16
Study 34933721 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanted cartilage tissue and implants
Number of subjects: 30
Study 34933721 — intervention group
Group type: COMPARATOR
Intervention: Implants only
Number of subjects: 30
Study 32516820 — intervention group
Group type: EXPERIMENTAL
Intervention: Video model of the hearing testing procedures
Number of subjects: 24
Study 32516820 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 34990776 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Trastuzumab Emtansine (T-DM1)
Number of subjects: 497
Study 34990776 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus Trastuzumab (TH)
Number of subjects: 497
Study 34990776 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Breast Radiation Therapy (WBRT) with T-DM1
Number of subjects: 497
Study 34990776 — intervention group
Group type: COMPARATOR
Intervention: Whole Breast Radiation Therapy (WBRT) with TH
Number of subjects: 497
Study 34990776 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 497
Study 34990776 — intervention group
Group type: COMPARATOR
Intervention: TH
Number of subjects: 497
Study 32707342 — intervention group
Group type: EXPERIMENTAL
Intervention: Simtuzumab
Number of subjects: 234
Study 32707342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 33012517 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ml kg−1 caudal injection of 0.2% ropivacaine
Number of subjects: 15
Study 33012517 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection pauses during caudal block
Number of subjects: 15
Study 33197159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 303
Study 33197159 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 303
Study 32553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 34
Study 32553878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 34
Study 34942228 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Mood Balance (MMB) paired with usual depression care (UDC)
Number of subjects: 109
Study 34942228 — intervention group
Group type: COMPARATOR
Intervention: Usual depression care (UDC)
Number of subjects: 109
Study 32029439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytarabine
Number of subjects: 591
Study 32029439 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose cytarabine
Number of subjects: 591
Study 32029439 — intervention group
Group type: EXPERIMENTAL
Intervention: Two courses of intermediate-dose cytarabine with daunorubicin or mitoxantrone
Number of subjects: 591
Study 35654569 — intervention group
Group type: EXPERIMENTAL
Intervention: Flossing
Number of subjects: 213
Study 35654569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthrinse
Number of subjects: 213
Study 35654569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of brushing, flossing, and mouthrinse
Number of subjects: 213
Study 35654569 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-habitual users
Number of subjects: 213
Study 35654569 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk perception of developing oral disease
Number of subjects: 213
Study 32556481 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-CNN slice-based approach
Number of subjects: 233
Study 32556481 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D-CNN case-based approach
Number of subjects: 233
Study 32556481 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CNN case-based approach
Number of subjects: 233
Study 36253765 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus peel extract (400 mg containing 0.1 mg of AUR and 3 mg of NAR)
Number of subjects: 80
Study 36253765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 34022138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal High-Flow Oxygen (NHFS) (40% O2, 40 L/min, 37 °C)
Number of subjects: 18
Study 34022138 — intervention group
Group type: COMPARATOR
Intervention: Conventional Nasal Cannula (5 L/min)
Number of subjects: 18
Study 34022138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal High-Flow Oxygen (NHFS)
Number of subjects: 18
Study 34022138 — intervention group
Group type: COMPARATOR
Intervention: Conventional Nasal Cannula
Number of subjects: 18
Study 32609069 — intervention group
Group type: EXPERIMENTAL
Intervention: Under body forced air heating
Number of subjects: 35
Study 32609069 — intervention group
Group type: COMPARATOR
Intervention: Over body forced air heating
Number of subjects: 35
Study 36404171 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Number of subjects: 1030
Study 36404171 — intervention group
Group type: COMPARATOR
Intervention: AZD1222
Number of subjects: 1030
Study 33884929 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly pain ratings
Number of subjects: 119
Study 33884929 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily pain ratings
Number of subjects: 119
Study 33884929 — intervention group
Group type: COMPARATOR
Intervention: Weekly ratings compared to daily ratings
Number of subjects: 119
Study 33884929 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly ratings
Number of subjects: 119
Study 33465293 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 0
Study 32059710 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline salivary methylation of Cg1307483 (NRF1)
Number of subjects: 92
Study 32059710 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline child BMI-Z
Number of subjects: 92
Study 36079806 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum
Number of subjects: 100
Study 36079806 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 33715657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0
Study 33715657 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0
Study 33715657 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant monotherapy
Number of subjects: 0
Study 35102419 — intervention group
Group type: EXPERIMENTAL
Intervention: HAW-R (High-Amylose Wheat Refined)
Number of subjects: 80
Study 35102419 — intervention group
Group type: COMPARATOR
Intervention: LAW-R (Low-Amylose Wheat Refined)
Number of subjects: 80
Study 34906099 — intervention group
Group type: EXPERIMENTAL
Intervention: Green health scenario (21121)
Number of subjects: 2854
Study 34906099 — intervention group
Group type: COMPARATOR
Intervention: Yellow health scenario (22222)
Number of subjects: 2854
Study 36160174 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine for scalp nerve block (SNB)
Number of subjects: 50
Study 36160174 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 50
Study 36401369 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 20
Study 36401369 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 20
Study 36401369 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 20
Study 35613418 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ganciclovir 0.15% ophthalmic gel (1 drop 3 times daily, n = 6 cats)
Number of subjects: 16
Study 35613418 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral famciclovir (90 mg/kg twice daily, n = 6)
Number of subjects: 16
Study 35613418 — intervention group
Group type: COMPARATOR
Intervention: Topical artificial tear gel (1 drop 3 times daily, n = 4)
Number of subjects: 16
Study 33814247 — intervention group
Group type: EXPERIMENTAL
Intervention: High target group (mean arterial pressure 85 mmHg)
Number of subjects: 78
Study 33814247 — intervention group
Group type: COMPARATOR
Intervention: Normal target group (mean arterial pressure 65 mmHg)
Number of subjects: 78
Study 36429924 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS with MI and upper-limb functional training
Number of subjects: 64
Study 36429924 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS with MI and upper-limb functional training
Number of subjects: 64
Study 32768690 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-item self-reported measure of adherence to medication
Number of subjects: 459
Study 32768690 — intervention group
Group type: COMPARATOR
Intervention: Claims-based adherence measures
Number of subjects: 459
Study 34124840 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil
Number of subjects: 24
Study 34124840 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil
Number of subjects: 24
Study 35670139 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 3318
Study 34010546 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT) with 15% velocity loss (VL15)
Number of subjects: 33
Study 34010546 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT) with 45% velocity loss (VL45)
Number of subjects: 33
Study 34010546 — intervention group
Group type: COMPARATOR
Intervention: Endurance Training (ET)
Number of subjects: 33
Study 36176445 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpi Huatan granule (JHG) for 3 months
Number of subjects: 350
Study 36176445 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 350
Study 36331315 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 284 mg
Number of subjects: 203
Study 36331315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 33229200 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaghetti (S)
Number of subjects: 0
Study 33229200 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice (R)
Number of subjects: 0
Study 33229200 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice (R) with Pesto (P)
Number of subjects: 0
Study 33229200 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaghetti (S) with Pesto (P)
Number of subjects: 0
Study 33229200 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice (R) with Extra Virgin Olive Oil (EVOO)
Number of subjects: 0
Study 33229200 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaghetti (S) with Extra Virgin Olive Oil (EVOO)
Number of subjects: 0
Study 33229200 — intervention group
Group type: COMPARATOR
Intervention: Rice (R) and Spaghetti (S) consumed plain
Number of subjects: 0
Study 35945594 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosa foetida extract capsules
Number of subjects: 0
Study 35945594 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 0
Study 35945594 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 0
Study 34770116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit-stand desk intervention
Number of subjects: 74
Study 32585581 — intervention group
Group type: EXPERIMENTAL
Intervention: Z5 (5 mg/kg/day)
Number of subjects: 36
Study 32585581 — intervention group
Group type: EXPERIMENTAL
Intervention: Z10 (10 mg/kg/day)
Number of subjects: 36
Study 32585581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 35128915 — intervention group
Group type: EXPERIMENTAL
Intervention: Big Data Telematics intervention
Number of subjects: 0
Study 35128915 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33612438 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Self-Administered 24-Hour Dietary Assessment Tool (ASA24-2016)
Number of subjects: 331
Study 33612438 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet History Questionnaire II (DHQ-II)
Number of subjects: 331
Study 33612438 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ASA24-2016 recalls and DHQ-II
Number of subjects: 331
Study 33612438 — intervention group
Group type: EXPERIMENTAL
Intervention: First ASA24-2016 recall
Number of subjects: 331
Study 33612438 — intervention group
Group type: EXPERIMENTAL
Intervention: DHQ-II
Number of subjects: 331
Study 32843320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 130
Study 32843320 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 130
Study 35171742 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced training group using Clip-Tone training aid linked to smartphone app
Number of subjects: 221
Study 35171742 — intervention group
Group type: COMPARATOR
Intervention: Verbal training group
Number of subjects: 221
Study 35171742 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 221
Study 34258913 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg, every night for 4 weeks)
Number of subjects: 64
Study 34258913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (evolocumab, 140 mg, once every 2 weeks on top of atorvastatin 20 mg per day)
Number of subjects: 64
Study 34258913 — intervention group
Group type: COMPARATOR
Intervention: Control group (Atorvastatin only)
Number of subjects: 64
Study 34915980 — intervention group
Group type: EXPERIMENTAL
Intervention: 5%-10% weight loss group (5%-10%WLG)
Number of subjects: 180
Study 34915980 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 10% weight loss group (≥ 10%WLG)
Number of subjects: 180
Study 34915980 — intervention group
Group type: EXPERIMENTAL
Intervention: < 5% weight loss group (< 5%WLG)
Number of subjects: 180
Study 34915980 — intervention group
Group type: COMPARATOR
Intervention: Weight-stable/gain group (WS/GG)
Number of subjects: 180
Study 32321768 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy
Number of subjects: 233
Study 32321768 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-line chemotherapy
Number of subjects: 233
Study 36239695 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) (ad libitum eating within 12 hours)
Number of subjects: 42
Study 36239695 — intervention group
Group type: COMPARATOR
Intervention: Standard dietary advice (SDA) (food pyramid brochure)
Number of subjects: 42
Study 36239695 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 42
Study 36239695 — intervention group
Group type: COMPARATOR
Intervention: Standard dietary advice (SDA)
Number of subjects: 42
Study 34284351 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 4 mg/kg
Number of subjects: 102
Study 34284351 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 2 mg/kg
Number of subjects: 102
Study 34284351 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 0 mg/kg (placebo)
Number of subjects: 102
Study 34284351 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (all doses)
Number of subjects: 102
Study 32529353 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular port placement
Number of subjects: 0
Study 32529353 — intervention group
Group type: COMPARATOR
Intervention: Midline port placement
Number of subjects: 0
Study 36132545 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing model (observation group)
Number of subjects: 142
Study 36132545 — intervention group
Group type: COMPARATOR
Intervention: Conventional model (control group)
Number of subjects: 142
Study 34049837 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (exercise + education) including bi-weekly supervised exercise sessions and 30 min of education for 16 weeks (8 weeks supervised + 8 weeks self-guided with phone coaching)
Number of subjects: 0
Study 34049837 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32039875 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the left angular gyrus (fifteen sessions of 1800 magnetic pulses)
Number of subjects: 28
Study 32039875 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (fifteen sessions)
Number of subjects: 28
Study 35905117 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education intervention delivered in 6 sessions to 40 participants and their family members
Number of subjects: 80
Study 35905117 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 80
Study 34604969 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) with 4.8 mL of SonoVue
Number of subjects: 232
Study 34604969 — intervention group
Group type: COMPARATOR
Intervention: Conventional transthoracic ultrasound (TUS)
Number of subjects: 232
Study 34604969 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS for lesions sized between 1-2 cm
Number of subjects: 232
Study 34604969 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS for lesions sized between 2-5 cm
Number of subjects: 232
Study 34604969 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS for necrotic lesions
Number of subjects: 232
Study 34604969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CEUS and TUS)
Number of subjects: 232
Study 34232137 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trial of CDI treatment in children
Number of subjects: 0
Study 34232137 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation in children
Number of subjects: 0
Study 35970020 — intervention group
Group type: EXPERIMENTAL
Intervention: Corbevax (two‐dose schedule with 28 days of interval between doses)
Number of subjects: 460
Study 35970020 — intervention group
Group type: EXPERIMENTAL
Intervention: Corbevax with 750 µg of CpG1018
Number of subjects: 460
Study 35970020 — intervention group
Group type: EXPERIMENTAL
Intervention: Corbevax
Number of subjects: 460
Study 32734461 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP3652 300 mg twice daily
Number of subjects: 287
Study 32734461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 35629175 — intervention group
Group type: EXPERIMENTAL
Intervention: MULTIPAP intervention based on the Ariadne principles (FP training and FP patient interviews)
Number of subjects: 593
Study 35629175 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 593
Study 33455117 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteosarcoma cell lines MG63 and HOS with methylation inhibitor
Number of subjects: 51
Study 33455117 — intervention group
Group type: EXPERIMENTAL
Intervention: MG63 cell line
Number of subjects: 51
Study 33455117 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-osteosarcoma)
Number of subjects: 51
Study 35485658 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises with an instructor and low‐intensity laser exposure
Number of subjects: 90
Study 35485658 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises with an instructor, low‐intensity laser therapy, and PLFEF
Number of subjects: 90
Study 35485658 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercises with an instructor
Number of subjects: 90
Study 32768874 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent MI and tCBT (iMI + tCBT)
Number of subjects: 36
Study 32768874 — intervention group
Group type: COMPARATOR
Intervention: tCBT and psychoeducation
Number of subjects: 36
Study 34160587 — intervention group
Group type: EXPERIMENTAL
Intervention: Development cohort (n=4172)
Number of subjects: 8403
Study 34160587 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort (n=4231)
Number of subjects: 8403
Study 32363972 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-infusion single-dose mesenchymal stem cells (1 × 10^6 cells/kg)
Number of subjects: 50
Study 32363972 — intervention group
Group type: COMPARATOR
Intervention: Control group without MSCs
Number of subjects: 50
Study 33300754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule of thirds for detecting excessive anterior acetabular wall coverage
Number of subjects: 161
Study 33300754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule of thirds for detecting excessive posterior acetabular wall coverage
Number of subjects: 161
Study 33300754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule of thirds for detecting deficient anterior acetabular wall coverage
Number of subjects: 161
Study 33300754 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule of thirds for detecting deficient posterior acetabular wall coverage
Number of subjects: 161
Study 34225296 — intervention group
Group type: EXPERIMENTAL
Intervention: Postinjury firearm weapon carriage
Number of subjects: 128
Study 34225296 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD symptom levels
Number of subjects: 128